Novartis v. Alkem et al.: ENTRESTO® Patent Battle Spans 1,786 Days
Novartis AG filed suit against more than fifteen generic manufacturers — including Alkem, Lupin, Teva, Aurobindo, Biocon, and Torrent — asserting four patents covering its blockbuster heart failure drug ENTRESTO® (sacubitril/valsartan). Filed in the Delaware District Court in October 2019, the case wound through nearly five years of litigation before closing in September 2024 when the last remaining defendants, Torrent, were terminated from the case.
Novartis Defends ENTRESTO® Against Wave of Generic ANDA Filers
In October 2019, Novartis AG initiated patent infringement proceedings in the Delaware District Court (Case No. 1:19-cv-01979) against Alkem Laboratories and a broad coalition of generic pharmaceutical companies — including Lupin, Teva, Aurobindo, Biocon, Laurus Labs, Crystal Pharmaceutical, S&B Pharma, Nanjing Noratech, and Torrent — asserting four U.S. patents: US8101659B2, US9388134B2, US8796331B2, and US8877938B2. All four patents relate to the sacubitril/valsartan compound and formulations underlying ENTRESTO®, Novartis’s FDA-approved treatment for heart failure with reduced ejection fraction, sold in 24/26 mg, 49/51 mg, and 97/103 mg tablet strengths.
The case was terminated on September 6, 2024, when the final defendants — identified in the record as ‘Torrent’ — were formally dismissed, closing the docket. The court record characterises termination as ‘Case Terminated’ without specifying whether individual defendants were resolved by consent judgment, settlement, or litigation victory. This pattern is typical of large ANDA multi-defendant cases where earlier-filed defendants are resolved on a rolling basis and the docket closes upon termination of the last remaining party.
A nearly five-year duration is not unusual for multi-defendant Hatch-Waxman litigation of this complexity: four patents, fifteen-plus defendants, and a high-value branded drug all contribute to extended timelines. The public record does not disclose the specific terms on which each defendant exited the case, leaving open questions about whether consent judgments of non-infringement, settlement agreements with market-entry dates, or default resolutions were used. What is clear is that Novartis pursued its exclusivity position aggressively and sustained the litigation through to the termination of every named defendant.
Filing to Case Terminated in 1786 days
1,786-day duration — nearly 5 years, consistent with complex multi-defendant ANDA patent litigation
Case terminated: what closing the docket means for each party
What ‘Case Terminated’ means in ANDA litigation
A ‘Case Terminated’ entry in a Hatch-Waxman docket does not by itself signal a merits ruling. In multi-defendant ANDA cases, defendants are typically resolved individually — through consent judgments, settlements fixing a market-entry date, or dismissal — and the docket closes when the last defendant is removed. The public record for this case is silent on the per-defendant mechanism, so no inference of win or loss should be drawn from the termination entry alone.
Procedural closureNovartis: exclusivity defended through full litigation lifecycle
By sustaining four-patent enforcement across fifteen-plus defendants for nearly five years, Novartis signals a determined posture in protecting ENTRESTO® exclusivity. Whether each defendant exited via consent judgment acknowledging patent validity, a negotiated market-entry date, or another mechanism is not publicly confirmed. However, the absence of any publicly reported generic launch during the litigation period is consistent with Novartis having successfully delayed or structured generic entry.
Exclusivity posture maintainedDefendants: resolution terms remain confidential
For the defendant generic manufacturers — including Alkem, Lupin, Teva, Aurobindo, Biocon, Laurus, and Torrent — the public record does not confirm whether any party obtained a ruling of non-infringement or invalidity, or whether exits were negotiated. Parties that settled likely secured a contractual market-entry date. The absence of a public judgment of invalidity means the four asserted patents remain formally intact as obstacles to generic launch absent individual agreement.
Terms not publicly confirmedENTRESTO® IP landscape: four patents still formally on the register
With no publicly recorded invalidity finding against any of the four patents, the sacubitril/valsartan IP estate remains formally enforceable. Any subsequent ANDA filer not party to this litigation — or any company developing a related sacubitril/valsartan formulation — would need to assess FTO risk against all four patents independently. The multi-defendant scope of this case underscores the breadth of Novartis’s enforcement strategy and the commercial stakes in the heart failure drug market.
Patent estate intact on recordFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Novartis, AG | Company | Global pharmaceutical innovator — holder of four sacubitril/valsartan ENTRESTO® patentsSearch in Eureka ↗ |
| Defendant | Alkem Laboratories, Ltd. | Company | 15+ generic manufacturers filing ANDAs to market sacubitril/valsartan tabletsSearch in Eureka ↗ |
| Co-Defendant | Others too numerous to list: Nanjing Noratech Pharmaceutical Co., Limited, Torrent Pharmaceuticals Ltd., Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc., Biocon Limited, Biocon Pharma Limited, Torrent Pharma Inc., Teva Pharmaceutical Industries Ltd., Biocon Pharma, Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | Lupin Limited | Individual | Search in Eureka ↗ |
| Co-Defendant | Lupin Pharmaceuticals, Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | Lupin Atlantis Holdings, S.A. | Company | Search in Eureka ↗ |
| Co-Defendant | Teva Pharmaceuticals USA, Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | Lupin, Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | S&B Pharma, Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | Laurus Generics Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Company | Search in Eureka ↗ |
| Co-Defendant | Laurus Labs Limited | Individual | Search in Eureka ↗ |
| Plaintiff counsel | Alexandra M. Joyce | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff counsel | Christina Schwarz | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff counsel | Daniel M. Silver | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff counsel | Deanne E. Maynard | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff counsel | Jared L. Stringham | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff counsel | Melinda R. Roberts | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff counsel | Nicholas N. Kallas | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff counsel | Whitney M. Howard | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff law firm | McCarter & English LLP | Law Firm | Representing Novartis, AGSearch in Eureka ↗ |
| Defendant counsel | Jane S. Berman | Attorney | Counsel for Alkem Laboratories, Ltd.Search in Eureka ↗ |
| Defendant counsel | Kenneth Laurence Dorsney | Attorney | Counsel for Alkem Laboratories, Ltd.Search in Eureka ↗ |
| Defendant counsel | Philip Y. Kouyoumdjian | Attorney | Counsel for Alkem Laboratories, Ltd.Search in Eureka ↗ |
| Defendant counsel | Roshan P. Shrestha | Attorney | Counsel for Alkem Laboratories, Ltd.Search in Eureka ↗ |
| Defendant counsel | Stephen R. Auten | Attorney | Counsel for Alkem Laboratories, Ltd.Search in Eureka ↗ |
| Defendant law firm | Morris James LLP | Law Firm | Representing Alkem Laboratories, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge Richard G. Andrews | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The docket closure entry — ‘CASE CLOSED as the last Defendants (Torrent) have been terminated from the case’ — is a procedural notation, not a merits adjudication. It confirms that no defendant remained active as of September 6, 2024, but is silent on the legal basis for each defendant’s departure. In Hatch-Waxman litigation, such notations typically follow a combination of consent judgments, voluntary dismissals, and settlement agreements resolved at different stages. Neither party should be characterised as having ‘won’ on the merits on the basis of this record entry alone.
US8101659B2, US9388134B2, US8796331B2 & US8877938B2 — ENTRESTO® Sacubitril/Valsartan
The four asserted patents — US8101659B2 (application no. US12/147570), US9388134B2 (US14/311788), US8796331B2 (US13/687659), and US8877938B2 (US11/722360) — collectively cover the sacubitril/valsartan active pharmaceutical ingredient, its salt and crystalline forms, pharmaceutical formulations, and related methods of manufacture and use. Together they form the core IP estate protecting ENTRESTO®, Novartis’s FDA-approved neprilysin inhibitor/angiotensin receptor blocker (ARNI) combination therapy indicated for heart failure with reduced ejection fraction. The earliest priority application (US11/722360) dates to the mid-2000s, reflecting years of pre-approval development investment.
ENTRESTO® is one of the most commercially significant cardiovascular drugs of the last decade, generating multi-billion dollar annual revenues for Novartis. The four-patent portfolio creates layered exclusivity: a challenger that successfully invalidates one patent still faces the remaining three. This stacking strategy is commercially deliberate — it raises the cost and complexity of generic entry and extends the effective exclusivity window. For competitors in the heart failure drug space, each of these patents represents an independent FTO obstacle that must be cleared or designed around before a generic sacubitril/valsartan product can enter the market.
Should you run an FTO analysis against these four ENTRESTO® patents?
Any company developing, formulating, or commercialising a sacubitril/valsartan product — whether as a generic, biosimilar-adjacent combination, or novel ARNI formulation — needs to assess freedom to operate against all four asserted patents individually. The fact that fifteen defendants litigated this case without any publicly confirmed invalidity finding means the patents remain formal obstacles. R&D teams working on heart failure combination therapies, ARNI formulations, or valsartan-containing fixed-dose combinations should prioritise FTO screening before committing to development pathways.
PatSnap Eureka’s FTO Search Agent can map each of the four patent numbers against your specific formulation, crystalline form, or manufacturing process parameters — identifying which claims are relevant, what prior art may support a validity challenge, and whether prosecution history estoppel limits claim scope. For teams tracking sacubitril/valsartan generic timelines, Eureka’s portfolio monitoring alerts you when assignment changes, continuation filings, or reexamination proceedings affect the live claim landscape.
Run a freedom-to-operate analysis on US8101659B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA patent cases: sacubitril/valsartan & cardiovascular drug IP
Explore related Hatch-Waxman infringement actions filed in Delaware District Court involving cardiovascular combination drug patents and multi-defendant ANDA challenges.
What this case signals for the cardiovascular pharmaceutical IP landscape
A five-year, four-patent, fifteen-defendant ANDA battle over ENTRESTO® sets a clear precedent for how Novartis defends blockbuster cardiovascular exclusivity.
Multi-defendant ANDA cases signal maximum exclusivity defence intent
Filing against fifteen-plus generics simultaneously — asserting four separate patents — is a deliberate strategy to maximise the 30-month stay under Hatch-Waxman and exhaust generic challengers through resource attrition. IP teams monitoring the cardiovascular space should expect comparable multi-wave enforcement from innovators with high-revenue assets like ENTRESTO®.
Four-patent stacking is a key risk multiplier for generic entrants
With US8101659B2, US9388134B2, US8796331B2, and US8877938B2 all asserted simultaneously, each generic filer faced compound invalidity/non-infringement challenges across distinct patent claims. Generic entrants who resolved without a merits ruling carry residual risk if their ANDA product profiles change. R&D teams should conduct FTO analysis against all four patents independently, not just the lead compound patent.
Novartis v Alkem — key questions answered
Novartis asserted four U.S. patents: US8101659B2, US9388134B2, US8796331B2, and US8877938B2. All four cover aspects of sacubitril/valsartan — the active combination underlying ENTRESTO® — including compound forms, crystalline structures, pharmaceutical formulations, and related methods.
The case closed on September 6, 2024, when the last defendants (Torrent) were terminated from the docket. The termination basis is recorded as ‘Case Terminated’ without specifying a merits ruling. In Hatch-Waxman cases this typically reflects a mix of settlements, consent judgments, and negotiated market-entry dates rather than a judicial finding of infringement or invalidity.
The defendants included Alkem Laboratories, Lupin Limited, Lupin Pharmaceuticals, Lupin Atlantis Holdings, Lupin Inc., Teva Pharmaceutical Industries, Teva Pharmaceuticals USA, Aurobindo Pharma, Aurobindo Pharma USA, Biocon Limited, Biocon Pharma Limited, Biocon Pharma Inc., Torrent Pharmaceuticals, Torrent Pharma Inc., Laurus Labs, Laurus Generics, Crystal Pharmaceutical (Suzhou), S&B Pharma, and Nanjing Noratech Pharmaceutical.
Based on the public record, no invalidity or non-infringement judgment was issued against any of the four patents. They remain formally on the register. Any new ANDA filer or formulation developer would need to assess FTO independently against US8101659B2, US9388134B2, US8796331B2, and US8877938B2, as prior case resolutions — likely confidential — do not confer rights on non-parties.
A 1,786-day duration is consistent with complex multi-defendant ANDA litigation involving four separate patents and fifteen-plus defendants. Individual defendants are typically resolved on different timelines depending on their ANDA filing dates, claim construction disputes, and settlement negotiations. The rolling resolution of defendants — with Torrent being the last — accounts for the extended total duration of the docket.
PatSnap Eureka searches patents and litigation data to answer instantly.